title: Renal cell carcinoma in the native and allograft kidneys of renal transplant recipients.
abstract: OBJECTIVE
  Renal cell carcinoma develops in renal transplant recipients 30 or more times more commonly than in the general population. We assessed the prevalence, histology and outcome of renal cell carcinoma in a large, single center recipient population.
  
  
  METHODS
  We examined outcomes in patients who underwent renal transplantation at our center to determine the prevalence, histology and outcome of those in whom renal cell carcinoma developed.
  
  
  RESULTS
  A total of 3,568 patients received a renal allograft at our institution between 1966 and 2009. A total of 45 renal cell carcinomas were diagnosed in the native kidney of 39 patients (1.1%) and in 8 (0.2%) renal cell carcinoma developed in the allograft kidney. Mean age at diagnosis was 51.6 and 48.2 years in patients with native kidney and allograft tumors, respectively. The mean interval between transplantation and the native or allograft renal cell carcinoma diagnosis was 10.6 and 12.1 years, respectively. Clear cell renal cell carcinoma was the most common tumor histology in native kidneys, diagnosed in 21 cases, while papillary renal cell carcinoma was diagnosed in 20. Five allograft tumors were papillary renal cell carcinoma and 3 were clear cell renal cell carcinoma. Native kidney tumors were managed by radical nephrectomy in 44 or by observation after biopsy. Allograft tumors were managed by transplant nephrectomy in 3 cases, radio frequency ablation in 3 and partial nephrectomy in 2. At a mean 6.6-year followup 32 patients with native kidney renal cell carcinoma were alive while 7 with allograft tumors were alive at a mean 3.6-year followup.
  
  
  CONCLUSIONS
  Renal cell carcinoma is more prevalent in patients with renal transplantation than the general population, although the subtype distribution differs. Excellent survival is seen at more than 6 years after treatment.
authors.affiliation: Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Michael
authors.initials: M
authors.lastname: Leveridge
authors.forename: Mireia
authors.initials: M
authors.lastname: Musquera
authors.forename: Andrew
authors.initials: A
authors.lastname: Evans
authors.forename: Carl
authors.initials: C
authors.lastname: Cardella
authors.forename: York
authors.initials: Y
authors.lastname: Pei
authors.forename: Michael
authors.initials: M
authors.lastname: Jewett
authors.forename: Michael
authors.initials: M
authors.lastname: Robinette
authors.forename: Antonio
authors.initials: A
authors.lastname: Finelli
mesh_terms: D002292:Carcinoma, Renal Cell / Q000453:epidemiology* / Q000209:etiology / Q000473:pathology*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000453:epidemiology* / Q000209:etiology / Q000473:pathology*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011379:Prognosis; D011446:Prospective Studies